Even though etomoxir reportedly blocks FAO by inhibiting CPT1 and suppressing GBM cell growth [19], our experimental results revealed that etomoxir is not effective in inhibiting drug resistance in GBM (data not shown). The gene discussed is CPT1A; the disease is glioblastoma.